This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
355
aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
decline of renal function
The aim of the study is to evaluate the decline of renal function, as assessed by absolute change in eGFR, calculated as the difference between eGFR at 3 years and baseline eGFR, in T2DM patients receiving low-dose aspirin (50 mg/d) or lacebo.
Time frame: 3YEARS
The rapid decline in renal function
The rapid decline in renal function, defined as a reduction of eGFR ≥5 mL/min at 1 year
Time frame: 3YEARS
Change of renal function class
Change of renal function class (from G1 to G2, from G2 to G3a, and so on) at 3 years, dialysis, or transplantation
Time frame: 3YEARS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.